Summa Equity Acquires Olink Proteomics
March 13, 2019
Summa Equity has acquired a majority stake in Olink Proteomics (Olink AB), a Uppsala-based life science company specializing in proteomics and protein biomarker discovery. The transaction is financed with senior secured/unitranche financing provided by EQT Credit and will support Olink's global scaling and continued product and service development.
- Buyers
- Summa Equity
- Targets
- Olink Proteomics (Olink AB)
- Industry
- Biotechnology
- Location
- Uppsala County, Sweden
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Thermo Fisher Scientific Acquires Olink Holding AB
July 10, 2024
Biotechnology
Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.
-
Summa Equity Acquires Majority Stake in Sengenics
October 14, 2020
Biotechnology
Summa Equity Fund II has acquired a majority stake in Sengenics, a functional proteomics company that commercialises the KREX technology for full‑length, correctly folded protein production and autoantibody detection. The investment will support Sengenics' product development, global expansion and accelerated commercial adoption across pharma, academic research and diagnostics.
-
Olink Proteomics Acquires Agrisera AB
May 12, 2020
Biotechnology
Olink Proteomics AB has acquired Agrisera AB, a Swedish antibody producer, to accelerate development and in‑house production of antibodies for Olink’s PEA immunoassay portfolio. The deal secures supply, lowers cost for customers, and expands Olink’s assay development capabilities by integrating Agrisera’s high-throughput antibody production.
-
Standard BioTools Acquires Sengenics from Summa Equity
November 21, 2024
Biotechnology
Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.
-
Summa Equity Acquires Majority Stake in Axion BioSystems
July 15, 2021
Medical Devices
Summa Equity Fund II has acquired a majority stake in Axion BioSystems, a US life science tools company that develops MEA (microelectrode array) and impedance-based bioelectronic assay technologies. Summa plans to support Axion's commercial scale-up and global growth to accelerate adoption of its platforms across academia and biopharma, particularly in cell and gene therapy and drug discovery applications.
-
Summa Equity Acquires Majority Stake in Logpoint
March 2, 2023
Cybersecurity
Summa Equity is acquiring a majority stake in Logpoint, the Copenhagen-based cybersecurity vendor, via its EUR 2.3bn Fund III to build a European cybersecurity powerhouse. The transaction leaves Yttrium as a significant minority shareholder and is subject to final regulatory approval (expected Q2 2023).
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.